Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.

Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review

Open access
Hanning, Nikita, Edwinson, Adam L., Ceuleers, Hannah, Peters, Stephanie A., De Man, Joris G., Hassett, Leslie C., De Winter, Benedicte Y., Grover, Madhusudan · 2021 · Therapeutic Advances in Gastroenterology

Abstract

BACKGROUND AND AIM: Irritable bowel syndrome (IBS) is a complex and heterogeneous disorder. Sensory, motor and barrier dysfunctions are the key physiological endophenotypes of IBS. Our aim is to review studies evaluating barrier dysfunction in adults and children with IBS, as well as to link those changes with IBS symptomatology and quality of life. METHODS: studies were considered. RESULTS: We identified 66 studies, of which 27 used intestinal probes to quantify barrier function. The prevalence of barrier dysfunction differed between PI-IBS (17-50%), IBS-D (37-62%) and IBS-C (4-25%). At a group level, permeability was increased compared with healthy controls in IBS-D (9/13 studies) and PI-IBS (4/4 studies), but only a minority of IBS-C (2/7 studies) and not in the only IBS-M study. All four studies in children with IBS demonstrated loss of barrier function. A heterogeneous set of tight junction genes were found to be altered in small and large intestines of adults with IBS, but these have not been evaluated in children. Positive associations were identified between barrier dysfunction and bowel disturbances (6/9 studies), abdominal pain (9/13 studies), overall symptom severity (1/6 studies), depression and anxiety (1/1 study) and quality of life (1/4 studies). Fecal slurry or supernatants of IBS patients were found to induce barrier disruption in animal models (5/6 studies). CONCLUSIONS: Barrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1756284821993586

Cites

138 of 138 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study schematic. Flowchart describing process for screening and selection of studies included in the systematic review.
Figure 1. Study schematic. Flowchart describing process for screening and selection of studies included in the systematic review.CC BY-NC · PubMed Central
Figure 2. Proportion of patients with increased in vivo permeability in the different IBS subtypes. IBS-D represented by the highest number of studies, which show a much higher proportion of patients (39–62%) with increased permeability. Larger studies tend to have a lower proportion of patients with increased permeability compared with smaller studies.* *Only studies that reported a proportion of IBS patients with increased permeability were included in this figure. Combination, ⩾1 subtype. IBS-C, constipation-predominant irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel syndrome; PI-IBS, post-infection irritable bowel syndrome.
Figure 2. Proportion of patients with increased in vivo permeability in the different IBS subtypes. IBS-D represented by the highest number of studies, which show a much higher proportion of patients (39–62%) with increased permeability. Larger studies tend to have a lower proportion of patients with increased permeability compared with smaller studies.* *Only studies that reported a proportion of IBS patients with increased permeability were included in this figure. Combination, ⩾1 subtype. IBS-C, constipation-predominant irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel syndrome; PI-IBS, post-infection irritable bowel syndrome.CC BY-NC · PubMed Central
Figure 3. Overview of in vitro and ex vivo barrier function changes in the different parts of the gastrointestinal tract of IBS patients. Most studies are available from the rectosigmoid colon, jejunum and the cecum and studied an IBS-D population. There is a significant heterogeneity in the target proteins assessed and the methodology used for determination of changes in vitro and ex vivo.* *Results of studies that did not specify the exact colonic region where biopsies were taken were not included in this figure, but are discussed in the main text.
Figure 3. Overview of in vitro and ex vivo barrier function changes in the different parts of the gastrointestinal tract of IBS patients. Most studies are available from the rectosigmoid colon, jejunum and the cecum and studied an IBS-D population. There is a significant heterogeneity in the target proteins assessed and the methodology used for determination of changes in vitro and ex vivo.* *Results of studies that did not specify the exact colonic region where biopsies were taken were not included in this figure, but are discussed in the main text.CC BY-NC · PubMed Central
Figure 4. Overview of studies reporting associations between barrier function and stool characteristics, abdominal pain, overall symptom severity, psychological functioning and quality of life in IBS patients. A positive association (red color) indicates study concluded barrier dysfunction to be positively correlated with a more severe symptomatology in IBS patients versus no correlation (blue color) versus a negative correlation (green color).§ §Gecse and colleagues found an association between an increased intestinal permeability and stool frequency, but no association between stool consistency and increased intestinal permeability. 51 Cr-EDTA, 51Cr-EDTA, chromium-51-ethylenediamine tetraacetic acid; CFL, cofilin; CLDN, claudin; JAM-1, junctional adhesion molecule 1; LMR, lactulose-to-mannitol ratio; PEGR, polyethylene glycol 400 to polyethylene glycol 3350 ratio; pMLC, phosphorylated myosin light chain; SER, sucralose-to-erythritol ratio; TEM, transmission electron microscopy; TESK1, testis-associated actin remodeling kinase 1; ZO, zona occludens.
Figure 4. Overview of studies reporting associations between barrier function and stool characteristics, abdominal pain, overall symptom severity, psychological functioning and quality of life in IBS patients. A positive association (red color) indicates study concluded barrier dysfunction to be positively correlated with a more severe symptomatology in IBS patients versus no correlation (blue color) versus a negative correlation (green color).§ §Gecse and colleagues found an association between an increased intestinal permeability and stool frequency, but no association between stool consistency and increased intestinal permeability. 51 Cr-EDTA, 51Cr-EDTA, chromium-51-ethylenediamine tetraacetic acid; CFL, cofilin; CLDN, claudin; JAM-1, junctional adhesion molecule 1; LMR, lactulose-to-mannitol ratio; PEGR, polyethylene glycol 400 to polyethylene glycol 3350 ratio; pMLC, phosphorylated myosin light chain; SER, sucralose-to-erythritol ratio; TEM, transmission electron microscopy; TESK1, testis-associated actin remodeling kinase 1; ZO, zona occludens.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 138 references

Research works printed but not linked: 3

  1. Paganelli R, 1990, Ann Allergy, 64, 377
  2. Mattioli F, 2011, Clin Lab, 57, 909
  3. Sun Q, 2019, Medicine (Baltimore), 98

Cited by

See all 240

Metadata

Authors
Hanning, N., Edwinson, A. L., Ceuleers, H., Peters, S. A., De Man, J. G., Hassett, L. C., De Winter, B. Y., & Grover, M.
Affiliations
  • Mayo Clinic (US)
  • University of Antwerp (BE)
  • Laboratory of Experimental Medicine and Pediatrics (LEMP) and Infla-Med, research consortium of excellence, University of Antwerp, Antwerp, Belgium
  • Division of Gastroenterology, Laboratory of Experimental Medicine and Pediatrics, Universiteitsplein 1, Antwerp, 2610, Belgium
  • Department of Medicine and Physiology, Enteric NeuroScience Program, 200 First St SW, Rochester, MN 55905, USA
Corresponding author
Grover, Madhusudan
Venue
Therapeutic Advances in Gastroenterology
Published
2021-01
Volume
14
Pages
1756284821993586-1756284821993586
ISSN
  • 1756-283X (ISSN-L)
  • 1756-2848
OpenAlex
W3135713284
Cited by
197
References
138
Citations by year
2026: 45 · 2025: 38 · 2024: 45 · 2023: 30 · 2022: 25 · 2021: 13
FWCI
5.39
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Gastroenterology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Universiteit Antwerpen (TOP 35018)
  • vlaamse instelling voor technologisch onderzoek (FWO-SBO S001017)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K23 103911, R03 120745)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Keywords
irritable bowel syndrome, intestinal barrier dysfunction, intestinal permeability, tight junction genes, post-infectious IBS, diarrhea-predominant irritable bowel syndrome, irritable bowel syndrome with constipation, IBS-M, pediatric IBS, abdominal pain, quality of life, animal models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. https://app.cochat.ai/papers/10.1177/1756284821993586
The paper
Hanning, N., Edwinson, A. L., Ceuleers, H., Peters, S. A., De Man, J. G., Hassett, L. C., De Winter, B. Y., & Grover, M. (2021). Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756284821993586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.